RxDoctor Payments Data

Sainte Elan Kim, NP

Family · Burlingame, CANPI 1669002093

Payments from drug & device makers

$1,738in general payments, 2019–2025

Across 100 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$395
  • Novo Nordisk$303
  • Amgen$256
  • Boehringer Ingelheim$211
  • Insulet Corporation$126
  • Dexcom, Inc.$106
  • plus $341 from 7 others

What the payments were for

  • Food & beverage$1,738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,738 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$85,910
Medicare patients
140
Services billed
2,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$108,029
TrulicityDulaglutide22$47,489
MounjaroTirzepatide30$46,144
JardianceEmpagliflozin28$43,812
Lyumjev Kwikpen U-100Insulin Lispro-Aabc15$21,672
JanuviaSitagliptin Phosphate13$20,401
FarxigaDapagliflozin Propanediol12$16,399
Testosterone61$15,265
Tresiba Flextouch U-100Insulin Degludec13$7,482
Novolog FlexpenInsulin Aspart19$5,192
Nano 2nd Gen Pen NeedlePen Needle, Diabetic22$2,441
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,983
Testosterone Cypionate19$1,329
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic18$1,318
Gabapentin14$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$303$108,02954 claims
Lilly USA, LLCTrulicity, Mounjaro$395$93,63352 claims
Boehringer IngelheimJardiance$211$43,81228 claims
MerckJanuvia$105$20,40113 claims
AstraZenecaFarxiga$59$16,39912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →